A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Amer M. Zeidan, Wei Wei et al.|Annals of Hematology|2023Cited by 23
Clinical Implications of <i>TP53</i> Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate DatabaseTariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 1
Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)Tariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 0
Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective AnalysisJan Philipp Bewersdorf, Amer M. Zeidan, Tariq Kewan et al.|Blood|2023Cited by 0